Day: May 7, 2020

Cortus Energys årsredovisning för 2019 finns från och med idag, torsdag den 07 maj, tillgänglig på bolagets hemsida: www.cortusenergy.comFör ytterligare information, vänligen kontakta;Håkan Sigfridsson, VD, Tel: +46 (0)8 588 866 30, www.cortusenergy.comOm Cortus EnergyCortus Energy (Publ) utvecklar och marknadsför den unika WoodRoll®-tekniken vilken förgasar biomassa på ett nytt innovativt sätt som resulterar i en rad unika fördelar gentemot all annan befintlig förgasningsteknik. Med den patenterade WoodRoll®-tekniken kan Cortus Energy erbjuda gröna energilösningar för kraft-, industri- och transporttillämpningar. WoodRoll® har stor bränsleflexibilitet, vilket innebär att processen kan utnyttja lågvärdiga förnybara bränslen utan att kompromissa med processprestanda. Cortus Energy har idag två WoodRoll® anläggningar, en testanläggning...

Selskabsmeddelelse nr. 14, 2020Holte, 7. maj 2020Indberetning af ledende medarbejderes og disses nærtståendes transaktioner med aktier i Investeringsselskabet Artha Optimum A/SHermed indberettes nedenstående oplysninger om ledende medarbejderes og disses nærtståendes transaktioner med selskabets aktier:KontaktKristian V. Myrup, direktør+45 70 25 00 05e-mail: info@arthakapitalforvaltning.dkMed venlig hilsenInvesteringsselskabet Artha Optimum A/SVedhæftet filSelskabsmeddelelse Optimum 2020 14 om ledende medarbejderes transaktioner

— Top-line interim data from nipocalimab Vivacity-MG study expected by Q3 2020 —— Full data from Part B of Phase 1/2 study of M254 in ITP expected in Q3 2020 —— Initiated IND-enabling studies for M267, a SIFbody candidate targeting CD38 —CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today reported its financial results for the first quarter ended March 31, 2020.“Despite the turbulence imposed by the COVID-19 pandemic, Momenta has remained focused on advancing our development pipeline for rare, immune-mediated diseases,” said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. “We are targeting...

STAMFORD, Conn., May 07, 2020 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, and Joana Goncalves, M.D., Chief Medical Officer, will participate in a fireside chat at the virtual BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 9:00 a.m. ET.A live webcast of the presentation can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately...

Piraeus, Greece, May 07, 2020 (GLOBE NEWSWIRE) — GasLog Ltd. (NYSE:GLOG) (“GasLog”) and GasLog Partners LP (NYSE:GLOP) (“GasLog Partners” or the “Partnership”) (together the “Group”) announced today that, following GasLog’s decision to base its senior management, including the Chief Financial Officer (“CFO”) position, in Greece, Alastair Maxwell has decided not to relocate and will therefore step down from his position as CFO on June 30, 2020.  The Boards of GasLog and GasLog Partners have appointed Achilleas Tasioulas, who is presently Deputy CFO, as CFO, effective July 1, 2020. During this period, Alastair will work closely with Achilleas to ensure an orderly transition of responsibilities and Alastair will remain available after leaving to provide his experience and advice, if required.Alastair Maxwell joined GasLog in February...

RESEARCH TRIANGLE PARK, N.C., May 07, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2020 Healthcare Conference on Thursday, May 14, 2020 at 9:00 a.m. ET and the 2020 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2020 at 3:40 p.m. ET. Both are being conducted as virtual conferences.About BioCryst Pharmaceuticals Links to a live audio webcast and replay of these presentations may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development...

Piraeus, Greece, May 06, 2020 (GLOBE NEWSWIRE) — GasLog Ltd. (NYSE:GLOG) (“GasLog”) and GasLog Partners LP (NYSE:GLOP) (“GasLog Partners” or the “Partnership”) (together the “Group”) announced today that, following GasLog’s decision to base its senior management, including the Chief Financial Officer (“CFO”) position, in Greece, Alastair Maxwell has decided not to relocate and will therefore step down from his position as CFO on June 30, 2020.  The Boards of GasLog and GasLog Partners have appointed Achilleas Tasioulas, who is presently Deputy CFO, as CFO, effective July 1, 2020. During this period, Alastair will work closely with Achilleas to ensure an orderly transition of responsibilities and Alastair will remain available after leaving to provide his experience and advice, if required.Alastair Maxwell joined GasLog in February...

NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal 2020 second quarter.“We are pleased to report that we are approaching the conclusion of the double-blind Phase 2 Parkinson’s disease dementia trial with ANAVEX®2-73 (blarcamesine) and we expect to report top line results by mid-2020,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “Both the Alzheimer’s disease Phase 2b/3 trial and clinical Rett syndrome programs are also...

AMRYT PHARMA PLC(“Amryt” or the “Company”)FILSUVEZ® CONFIRMED AS GLOBAL BRAND NAME FOR AP101Amryt, a global, commercial-stage biopharmaceutical company dedicated to commercializing and developing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces that the global brand name for its lead development product AP101 will be FILSUVEZ®.Amryt announced on 23 April 2020 that the Company has completed recruitment into its Global Phase 3 clinical study (“EASE”) in Epidermolysis Bullosa (“EB”) and anticipates top line data read out in late Q3 / early Q4 2020.Establishing the brand name for AP101 is another important step forward in ensuring readiness for the global launch of FILSUVEZ®.About EBEB is a rare and distressing genetic skin disorder affecting young children and adults for which...

Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned;Updated data from the Phase 1/2 InSight extension study of sepofarsen, including data from contralateral eye treatment, on track to be reported in H2 2020;Three clinical stage RNA therapies in development for inherited retinal diseases, with fourth ophthalmic program slated to enter mechanistic proof-of-concept studies;ProQR anticipates its cash runway will fund operations into H2 2022LEIDEN, Netherlands & CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) —  ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases,...